Thinly traded micro cap Kaleido Biosciences (KLDO +10.5%) is up on below-average volume, a modest 39K shares, on the heels of its announced advancement of candidate KB174 for the potential treatment of hepatic encephalopathy, a decline in brain function due to severe liver disease.
The company made its decision based on results from a proof-of-concept study that showed a 26% reduction in a biomarker of microbiome ammonia production in patients with well-compensated cirrhosis while being well-tolerated.
KB174, one of the company’s Microbiome Metabolic Therapy (MMT) candidates, is designed to lower ammonia and multidrug-resistant pathogens in the body by modulating the metabolic output and profile of the microbiome.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.